NIHR and OLS newly funded early cancer diagnostic projects include BIVDA member

The NIHR and the Office for Life Sciences (OLS) have funded six projects through the NIHR's Invention for Innovation (i4i) and the OLS Cancer Programme. This includes BIVDA member, Proteotype Diagnostics, who have developed a multi-cancer detection test which measures patient plasma amino acid cross sections. The six projects are receiving almost £11 million to support further testing of innovations…